A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2004
11/18/2004	US20040228959 Water soluble hemicellulose derived from soybean cotyledon mixed with perfume and colorant; foods, beverages, cosmetics; storage stability
11/18/2004	US20040228936 Administering cocoa extracts including procyanidin monomers and oligomers to treat inflammation, atherosclerosis, and cardiovascular disorders; bactericides, foods; cyclooxygenase and/or lipoxygenase inhibitors
11/18/2004	US20040228935 Plant extract comprising steroidal glycosides from the genus Trichocaulon or Hoodia produced by solvent extraction
11/18/2004	US20040228933 Method for normalizing insulin levels
11/18/2004	US20040228932 Excipient made by mechanically separating fiber rich fraction of Trigonella foenum-graceum seeds from embryos; binders, disintegrants, fillers, dispersants, thickeners; time-release agents; drug delivery
11/18/2004	US20040228931 Soy component, chasteberry, clover, and black cohosh, carrier, enrobed in a glycoprotein matrix; menopause, thyroid disease, stress, endometriosis, and cancer treatment in women
11/18/2004	US20040228924 Pharmaceutical products
11/18/2004	US20040228923 Pulmonary delivery in treating disorders of the central nervous system
11/18/2004	US20040228922 A crosslinked thermosensitive cellulose gel on a medical device and loaded with a solute is positioned within the body and heated to body temperature to release the solute upon gel shrinkage
11/18/2004	US20040228921 Compositions and methods for delivery of therapeutic agents
11/18/2004	US20040228919 A non-compressed, fast-dispersing solid dosage form suitable for oromucosal administration; maltodextrin having a dextrose equivalent (DE) of between 1 and 20, sorbitol, and the drug; improved storage stability and mechanical strength
11/18/2004	US20040228918 A naproxen once-a-day matrix tablet containing homogenous naproxen and organic acid granules with a film forming binder, a hydrogel forming polymer, and an enteric coating allowing immediate release of the naproxen formed by granulation, milling, compression and coating
11/18/2004	US20040228917 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
11/18/2004	US20040228916 Spray coating insoluble drug particles dissolved in a plasticizer with a solvent-free, powdered enteric coating agent; improved bioavailability and solubility; pollution control
11/18/2004	US20040228915 coated core particles of clindamycin are overcoated with a binder-dispersing agent, such as povidone; streptococci, pneumococci, and staphylococci infections
11/18/2004	US20040228914 Formulation
11/18/2004	US20040228913 complexed with the active agent; matrices, gels, hydrogels, films, emulsions or microparticles; personal care products, cosmetics
11/18/2004	US20040228912 Once daily formulations of tetracyclines
11/18/2004	US20040228911 Vinorelbine compositions and methods of use
11/18/2004	US20040228910 Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
11/18/2004	US20040228909 Compositions and methods for treating lymphoma
11/18/2004	US20040228906 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
11/18/2004	US20040228904 a fibrous nonwoven substrate treated with a readily releasable microbiocide that is released when introduced to a water source, and an anionic binder; antiseptics
11/18/2004	US20040228886 such as very low density hollow polymeric microspheres and temperature-sensitive expandable thermoplastic microspheres; gel beads; self-supporting; bulk density; storage stability
11/18/2004	US20040228883 Prepackaged aqueous pharmaceutical formulation for the treatment of cardiac conditions containing at least two different active agents and method of formulation
11/18/2004	US20040228880 Vaccine composition comprising iron phosphate as vaccine adjuvant
11/18/2004	US20040228879 Streptococcus pneumoniae polysaccharide is conjugated to protein or peptide, and RSV antigen with adjuvant which is stimmulator of (cytotoxic T) lymphocytes
11/18/2004	US20040228865 Prevention and treatment of amyloidogenic disease
11/18/2004	US20040228833 specific combination of excipients exhibits an increase of bioavailability of the polypeptide; namely a sugar and salting-out salt are present in sustained release composition
11/18/2004	US20040228823 for drug delivery, particularly in cancer as a tumor-specific delivery system
11/18/2004	US20040228808 Inhaling formulation providing analgesia to patient; contains one rapid-onset opioid and a sustained-effect opioid; avoiding toxicity while achieving analgesia, side effect occurs before the onset of toxicity; dispensers
11/18/2004	US20040228807 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
11/18/2004	US20040228806 For use in therapy of chronic obstructive pulmonary disease and asthma; an inhalette capsule contains a mixture of coarser and fine excipient particles
11/18/2004	US20040228805 Synergistic effect for treating respiratory disorders; a capsule containing inhalable powder for asthma or COPD; active 3-oxa-9-azatricyclo(3,3,1,0(2,4))nonane ring compound
11/18/2004	US20040228803 Sleeve and micro-encapsulated topical analgesic for pain relief
11/18/2004	US20040228802 Dosage forms when the drug is properly administered, free of bitter taste, no coloring; when administering not follow the instructions, crushed or extracted and nasally, orally, buccally or sublingually administered, drug will taste bitter, forming color to stain human tissue
11/18/2004	US20040228794 Therapeutic agent carrier compositions
11/18/2004	DE4124409B4 Pharmazeutische Zubereitungen Pharmaceutical preparations
11/18/2004	DE10358306B3 Cosmetic and dermatological oxygen carrier system useful in topical formulations comprises a liquid fluorocarbon, a liquid silicone and oil or water
11/18/2004	DE10326188A1 Aqueous silicone oil emulsion for use, e.g. in heat-sterilizable pharmaceuticals, comprises a non-ionic surfactant and shows a change of not more than 20 percent in particle size of the oil phase after heat-sterilization
11/18/2004	DE10319458A1 Arzneiform und Verfahren zu ihrer Herstellung Dosage form and processes for their preparation
11/18/2004	DE10319450A1 Pharmazeutische Formulierung des Telmisartan Natriumsalzes The pharmaceutical formulation of telmisartan sodium salt
11/18/2004	DE10319315A1 Verwendung eines amorphen Polyesters als Polymerbasis für Kaumassen Use of an amorphous polyester as polymer base for gum bases
11/18/2004	DE10315917A1 Hochreine Basen von 3,3-Diphenylpropylaminmonoestern High purity bases of 3,3-Diphenylpropylaminmonoestern
11/18/2004	CA2526508A1 Mechanical apparatus and method for dilating and delivering a therapeutic agent
11/18/2004	CA2524924A1 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer
11/18/2004	CA2524912A1 An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
11/18/2004	CA2524891A1 Ultraviolet-shielding type patch
11/18/2004	CA2524773A1 Particulate coformulations of active substances with excipients
11/18/2004	CA2524478A1 Lipid platinum complexes and methods of use thereof
11/18/2004	CA2524368A1 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
11/18/2004	CA2524286A1 Nasal administration of the lh-rh analog leuprolide
11/18/2004	CA2524029A1 Rf medical device
11/18/2004	CA2523709A1 Abuse-resistant transdermal dosage form
11/18/2004	CA2523620A1 Drug releasing biodegradable fiber for delivery of therapeutics
11/18/2004	CA2523425A1 Abuse-resistant transdermal dosage form
11/18/2004	CA2523417A1 Method for storing tumor cells
11/18/2004	CA2522529A1 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
11/18/2004	CA2521928A1 Freeze-dried preparation containing methylcobalamin and process for producing the same
11/18/2004	CA2504493A1 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
11/18/2004	CA2504268A1 Nanoparticulate bioactive agents
11/17/2004	EP1477541A1 Pressure sensitive adhesive and patch employing the same
11/17/2004	EP1477189A1 Process for production of pressure-sensitive adhesive moldings comprising crosslinked polymers as the main component
11/17/2004	EP1477187A1 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
11/17/2004	EP1477182A1 Novel analgesics
11/17/2004	EP1477178A2 Health supplements containing phyto-oestrogens, analogues or metabolites thereof
11/17/2004	EP1477177A1 Process for producing hydrophobic glycyrrhiza extract with high qualities
11/17/2004	EP1477171A1 Intestinal mineral absorption capacity improver
11/17/2004	EP1477169A1 Reactions of polymorphs of N-methyl-N-(3-(3-(2-thienylcarbonyl)-pyrazol-(1,5-alpha)-pyrimidin-7-yl)phenyl)acetamide
11/17/2004	EP1477164A1 Percutaneous absorption type plaster
11/17/2004	EP1477163A1 New film coating
11/17/2004	EP1477162A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/17/2004	EP1477161A1 Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof
11/17/2004	EP1477119A1 Drug administration method
11/17/2004	EP1476531A2 Scented polymer capsules and the production thereof
11/17/2004	EP1476492A1 Carbohydrate-modified polymers, compositions and uses related thereto
11/17/2004	EP1476454A1 Binding epitopes for helicobacter pylori and use thereof
11/17/2004	EP1476206A1 Compositions comprising undifferentiated fetal cells for the treatment of skin disordes
11/17/2004	EP1476199A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
11/17/2004	EP1476196A1 Oral solid solution formulation of a poorly water-soluble active substance
11/17/2004	EP1476193A1 A weight management system for obese animals
11/17/2004	EP1476191A2 Oral administration of interferon-tau
11/17/2004	EP1476178A2 Formulation strategies in stabilizing peptides in organic solvents and in dried states
11/17/2004	EP1476173A1 Outer membrane vesicles from gram negative bacteria and use as a vaccine
11/17/2004	EP1476168A2 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
11/17/2004	EP1476159A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof
11/17/2004	EP1476142A1 Compositions for pulmonary administration
11/17/2004	EP1476141A2 Tamper-resistant transdermal opioid delivery devices
11/17/2004	EP1476140A1 Taste-masked film-type or wafer-type medicinal preparation
11/17/2004	EP1476139A1 Controlled release dosage forms
11/17/2004	EP1476138A2 Modified release formulations of at least one form of tramadol
11/17/2004	EP1476137A1 Composition comprising low water soluble compounds within porous carriers
11/17/2004	EP1476136A1 Pharmaceutical composition comprising n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation
11/17/2004	EP1476135A1 Ophthalmic formulation with gum system
11/17/2004	EP1476130A1 Preparations containing diol
11/17/2004	EP1476127A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity
11/17/2004	EP1476032A1 Water dispersible coenzyme q10 dry powders
11/17/2004	EP1476019A1 Aqueous antiseptic based on bispyridiniumalkanes
11/17/2004	EP1390063B1 Pharmaceutical dosage form of amorphous nelfinavir mesylate
11/17/2004	EP1303297B1 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency

1 ... 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 ... 2991